Clinical trial
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First…
NCT00290953 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00290953 |
|---|---|
| Title | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide |
| Official title | A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide |
| Acronym | SESAME |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | SR48692 |
| Enrollment | 432 |
| Start date | Oct 1, 2002 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Feb 13, 2006 |
| Last update posted | Dec 23, 2008 |
| Countries | Argentina, Australia, Belgium, Brazil, France, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Russia and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: